Study of NTx®-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients
Status:
Terminated
Trial end date:
2010-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is:
- To assess the neurological outcome in acute ischemic stroke patients treated with
NTx®-265, when compared with patients given a placebo control.
- To assess the safety and tolerability of NTx®-265 when given to acute ischemic stroke
patients.